Companies To Watch

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.

  • Companies To Watch: United Neuroscience
    Companies To Watch: United Neuroscience

    “We are a vaccine company,” says CEO Mei Mei Hu. “We’re developing a new class of vaccines for endogenous proteins, leveraging a commercially successful technology platform in which we’ve invested more than 20 years.”

  • Companies To Watch: Acceleron
    Companies To Watch: Acceleron

    Acceleron has four drugs in development in the hematology, neuromuscular, and pulmonary disease areas. Its lead drug luspatercept has completed Phase 3 trials for treating myelodysplastic syndromes (MDS).

  • Companies To Watch: Sensorion
    Companies To Watch: Sensorion

    This French company is addressing vertigo and hearing loss inside the inner ear.

  • Companies To Watch: Landos Biopharma
    Companies To Watch: Landos Biopharma

    Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.

  • Companies To Watch: CytoDyn
    Companies To Watch: CytoDyn

    CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.

  • Companies To Watch: AmpliPhi Biosciences
    Companies To Watch: AmpliPhi Biosciences

    AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

  • Companies To Watch Roundup 2017
    Companies To Watch Roundup 2017

    We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.

  • Companies To Watch: Zavante
    Companies To Watch: Zavante

    This month’s Company To Watch is 10-person Zavante, which is challenging drug resistance with a retooled antibiotic and a broad mechanism of action.

  • Companies To Watch: Daré Bioscience
    Companies To Watch: Daré Bioscience

    Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.

  • Companies To Watch: Abivax
    Companies To Watch: Abivax

    With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection.  It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).

  • Companies To Watch: Madrigal Pharmaceuticals
    Companies To Watch: Madrigal Pharmaceuticals

    Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.

  • Companies To Watch: Arena Pharmaceuticals
    Companies To Watch: Arena Pharmaceuticals

    By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.

  • Companies To Watch: ProMIS Neurosciences
    Companies To Watch: ProMIS Neurosciences

    ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.

  • Companies To Watch: GeNeuro
    Companies To Watch: GeNeuro

    Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.

More Companies To Watch articles

BEYOND THE PRINTED PAGE

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • The Future Of Biopharma — Netherlands Style
    The Future Of Biopharma — Netherlands Style

    Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.

  • What Mylan Could Learn About Accountability
    What Mylan Could Learn About Accountability

    Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.

More From Life Science Leader Blogs

@LIFESCILEADER1